Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 77

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 77
---
209,232   2.9                  %           203,450   3.1                  %           250,165   4.0                  %
Intersegments                                            —          —             ​                 —          —             ​           (8,948)                (0.1)   %
Total                                            7,212,382   100.0                %         6,591,977   100.0                %         6,063,967   100.0                %
​
The Biopharma Business Unit
The Biopharma business unit is responsible for the research and development, production and marketing of plasma derivative products. In 2024, the Biopharma business unit accounted for 85.2% of our total net revenue.

46

<{self.tag} alt="{self.alt}" src="{self.src}">Operational Structure
The following chart illustrates its operational structure:
From plasma donation to therapeutic application, there are four major steps in the industry value chain process: (i) plasma collection, (ii) transport and logistics, (iii) manufacturing (fractionation and purification) and (iv) marketing and distribution. We are present at all levels of the value chain, from collection centers to distribution of the final products. This vertical integration enables us to leverage our position at each stage to control the overall process, to benefit from lower prices and to introduce complementary products, such as those offered through the Diagnostic business unit, to our customers.
Plasma Procurement
Plasma is the key raw material used in the production of plasma-derived products. We have expanded our plasma collection network through a combination of organic growth by opening new plasma collection centers and acquisitions. We obtain our plasma primarily from the United States and Europe (Germany, Austria, Czech Republic, and Hungary) through more than 400 operating plasma collection centers and, to a much lesser extent, through agreements with third parties. Over the last few years, pursuant to the implementation of our business strategy, we have acquired plasma collection centers in the United States, Canada and Europe. 

47

In 2024, our plasma collection remained at the same level as in 2023, and the average cost per liter of plasma collected in 2024 declined by 4.4% in comparison to the average cost per liter in 2023. We also increased our plasma collection center optimization in 2024 with an upturn in unique donors to 930,000 people, an increased donor frequency and the new installation of more